May 5, 2021 Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results
April 28, 2021 Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021
April 14, 2021 Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
April 1, 2021 Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
February 25, 2021 Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021
December 22, 2020 Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol
November 16, 2020 Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options
November 12, 2020 Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
